Kadmon Holdings, Inc.:
Announced pos. primary analysis results (May 2020) in pivotal trial of ROCK inhibitor-KD025 (Belumosudil) in cGVHD pts receiving 2+ prior therapy lines; ORRs of 73% and 74% in 200mg QD and 200mg BID arms, respectively. Belumosudil is being reviewed under Real-Time Oncology Review (RTOR) Pilot Program by the FDA; NDA submission exp Q4 2020. Enrolling pts in Ph 2 trial (sys. sclerosis).
US - Middle Atlantic
Phase l or ll
Autoimmune, Fibrosis, Immunotherapy, Oncology
500MM - 1B
450 East 29th Street
New York, NY 10016
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Chronic Graft-Versus-Host Disease
Idiopathic Pulmonary Fibrosis
Top 10 Holders of Kadmon Holdings Inc Warrant 2017-28.09.22 On Kadmon Hldngs
Top 10 Holders of Kadmon Holdings, Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by